[Use of mildronate in therapy of seroresistant syphilis (serologic and immunologic comparisons].
Clinico-serological and immunological examinations were applied to 84 patients suffering from seroresistant syphilis with positive serological reactions within 1.5 to 10 years after termination of the treatment by various methods. The initial diagnosis of recently inflicted secondary syphilis was recorded in 8.9 per cent of the patients. 43.3 and 47.8 per cent of the patients had secondary relapsing syphilis and early occult syphilis, respectively. The percentage of lymphocytes CD3+, CD4+, CD8+ and HLA DR+ was determined in peripheric blood with the monoclonal antibodies OKT-3+, OKT-4+, OKT-8+ and FITC-labeled antimouse Ig. The quantity of IgA, IgG and IgM was determined by radial immunodiffusion. The immunoregulatory index (IRI, the ratio of T-helper/inductor cells and T-suppressor cells/cytotoxics) was calculated. The use of mildronate, a drug developed at the Institute of Organic Chemistry of the Academy of Sciences of the Latvian SSR (Riga), led to normalization of the impaired immunological indices and complete negativation of the serological reactions in the group of the patients with disorders in the immunity status (CD8+ - 33 per cent and IRI - 1.3), p less than 0.01.
Glozman
V N
VN
Berenbeĭn
B A
BA
Kirmane
R E
RE
Pervushina
N V
NV
Shur
A A
AA
Agranovskiĭ
V B
VB
D000328:Adult; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008763:Methylhydrazines / Q000627:therapeutic use*; D008875:Middle Aged; D013587:Syphilis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D013588:Syphilis Serodiagnosis
D008763:Methylhydrazines; C050147:3-(2,2,2-trimethylhydrazine)propionate
Primenenie mildronata v terapii serorezistentnogo sifilisa (serologicheskie i immunnye paralleli).